Pattern of tumor progression in liver cancer: The missing partner in trial design.

@article{Reig2015PatternOT,
  title={Pattern of tumor progression in liver cancer: The missing partner in trial design.},
  author={Mar{\'i}a Elisa Reig and Jordi Bruix},
  journal={Hepatology},
  year={2015},
  volume={62 3},
  pages={674-6}
}
T he success of sorafenib has prompted a major research activity in the systemic treatment of hepatocellular carcinoma (HCC). This includes phase II and III trials, which aim to improve the benefits of sorafenib, and real-life studies to better understand the mechanisms of action and the factors associated to better or worse survival of treated patients. To date, all phase III trials in first line versus sorafenib or in combination with other agents, and trials in second line versus placebo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…